Pfizer/Wyeth Layoff Update
.jpg)
After announcing yesterday that it will be reorganizing and closing 6 of 20 R&D sites worldwide, Pfizer/Wyeth announced today that as many as 2000 R&D scientists will lose their jobs. I suspect that others will lose their jobs in the next few months or so.
The Pfizer/Wyeth and Merck Schering Plough mergers signal the beginning of the end of the traditional vertically integrated pharmaceutical business model. It is evident that pharma is shifting away from its almost 100 year focus on R&D and manufacturing to less labor intensive and costly activities like advertising, marketing, sales and distribution—things that drug makers have excelled in the past decade or so. Innovation will likely no longer come from within but from external sources including academia, biotechnology companies and third party vendors including CROs and CMOs.
While the loss of thousands of R&D scientists will have little impact on the productivity and operations of life sciences companies themselves, it has serious implications for academic institutions that train life sciences graduate students and postdoctoral fellows. In the past, PhD scientists who were unable to find academic jobs too refuge and found gainful employment in the life sciences industry. However, American industrial R&D jobs are becoming harder and harder to find as larger companies continue to outsource those activities, to Asia, South America and Eastern Europe. And, the competition for the remaining jobs is becoming increasingly fierce. Put simply, academic institutions have to begin to realize that we no longer need as many PhD-trained life scientists as we have in the past. At present, there is a glut of PhD life scientists in the US, many of whom can’t find jobs. Perhaps, this should be taken into account before graduate school admissions committees determine the number of new graduate students they will admit next year.
Until next time...
Good Luck and Good Job Hunting!!!!!!!!!!!
.jpg)
In today’s edition of the incisive EyeonFDA blog, Mark Senak, provides a 
Employees of Pfizer/Wyeth were notified earlier today of impending changes and consolidation that will be taking place at the newly combined company. According to internal sources, Cambridge, MA, Groton, CT and Pearl River, NY will be the main centers of the combined company’s East Coast operations and San Francisco and La Jolla/San Diego CA will represent West Coast operations. In Europe, the research facility in Sandwich, England will be the main R&D center with a network of smaller sites, in locations such as Montreal, Ottawa, Cambridge UK, Aberdeen UK, and Dusseldorf, Germany providing expertise in vaccine production and biomanufacturing. The company’s China R&D Center in Shanghai will remain the focal point of operations in Asia,
I am attending the 
It is amazing the things you learn if you pay attention from time to time. While attending a meeting on e-healthcare last week in Philadelphia I learned that according to the American public the pharmaceutical industry is less popular than the banking industry. This was startling to me given that the recent financial collapse was caused almost entirely by the banking industry. That the pharmaceutical industry is more reviled than the banking industry suggests that life sciences company have a bit of PR work to do. But, not to worry, people still hate the oil industry more than the pharmaceutical industry.(1).png)
e-Patients Connections 2009 .jpg)
The.jpg)
An annual survey conducted by Science magazine and the American Association has identified the .gif)
NextLevel Pharma 
.gif){kind=icon}
Lisa Roner, blogger and editor for EyeforPharma, recommends a podcast on social media that was created by Dr. Andree Bates, CEO at Eularis, a company that applies analytics to determine the sales impact of specific marketing programs.
BioCrowd co-founder, .png)
Berci Meskó author of the .png)
During my recent trip to Vermont and Woodstock, NY I had several conversations about Twitter. Surprisingly, I was being asked to explain Twitter to my nephews, both of whom are in their early 20s and to family friends who are in their late 40s and beyond. Also, at several recent science career fairs that I attended many graduate students and postdocs had never heard of Twitter or it they had, they don’t use it. Initially, this was puzzling but after considering the most recent Twitterverse demographics –I think the average age of Twitter users is around 35 to 40—it made more sense to me.
Like it or not, writing a carefully-constructed resume or curriculum vitae (as resumes are known in scientific circles) is a vital part of any successful job search. Inexperienced job seekers tend to hastily craft resumes without paying much attention to format, style or content and then wonder why they can’t land job interviews. The best way to approach resume writing is to think of a resume as a work of art–something that requires a lot of thought, creativity and attention to detail. As one well-known professional recruiter and job search expert put it”Trying to find a job without a smart, well-crafted resume is like showing up for dinner at a fancy restaurant in a T-shirt and cutoffs. They won’t let you in.” 
While the economy is showing signs of a possible recovery, the unemployment numbers continue to rise. For this reason, it is a good idea to keep your resume as up-to-date as possible. Yes, I know it is a hassle to update and stay on top of you resume especially if you already have a job. However, in these uncertain financial times, you never know when you might be back on the job market. To that end, I highly recommend a piece on .jpg)
Pharmaceutical,biotechnology and other companies that sell prescription drugs and devices are deathly afraid of adverse events (AEs) associated with their products. For those of you who may not know, companies with approved prescription drugs and medical devices are required to track and report any adverse events associated with their products to regulatory agencies like the US Food and Drug Administration (FDA). If FDA receives enough AE complaints about a product, the agency will investigate to determine whether or not there may be efficacy, safety or tolerability issues with it. And, if FDA thinks that the AEs are legitimate, it may ask a company to conduct Phase IV clinical trials with the product in question or require that changes be made to the product’s label. Not surprisingly, these outcomes can be time consuming and perhaps more importantly, costly. Label changes—especially for blockbuster products—frequently lead to changes in physician prescribing habits which can translate into a loss of revenue. Despite the fact that ALL drugs exhibit AEs, many companies falsely cling to the hope that there will be few, if any, AEs reported for their products..jpg)
Mark Senak, author of the 
I met .jpg)
Until today, direct-to-consumer advertising (DTC) has received very little attention during the recent spate of debates over healthcare reform. The (1).jpg)
The debate, if you can call it that, over whether or not interactive social media platforms like .jpg)
Mark Sendak, a social media enthusiast and author of the 
Over the past several years, I have publicly called for fundamental changes in graduate education and training for life scientists. To that end, I was delighted to read an OP-ED piece in today’s New York Times entitled “End Universities as We Know It” written by Professor Mark C. Taylor, Chairperson of the religion department at Columbia University. .jpg)
The New York Times reported 
Twitter, which is currently de rigueur in social media circles, is emerging as one of the most powerful branding and marketing social media tool that has been developed to date. 
Since 2007, approximately 80,000 pharmaceutical jobs have been eliminated. The recent consolidation in the industry, e.g., Merck-Schering, Pfizer-Wyeth and Roche-Genentech suggests that many more life sciences jobs will be lost over the next year or so. Typically, to avoid law suits and possible discrimination claims, most companies will layoff a mixture of experienced and entry level employees that cover the racial, religious and age spectra. For those of you who may not know, Americans who are 40 and older constitute a “protected class of employees.” In other words, companies that layoff employees cannot disproportionately give pink slips to employees 40 years of age or older. This law was enacted because older employees typically have higher salaries and have accrued more benefits and vacation time than their more junior counterparts and eliminating them can drastically cut costs. While most companies are careful to layoff a mixture of junior and senior employees during large layoffs, a quick perusal of the demographics of employees who lose their jobs reveals that many of them are older, more experienced workers. Sacrificing a few entry level employees (to prevent any red flags) is worth it to the accountants who charged with cutting costs and orchestrating large corporate layoffs..jpg)
Today's New York Times reported that the US Food and Drug Administration (FDA) issued warning letters and ordered 14 pharmaceutical and biotechnology companies to stop running what it calls misleading ads on internet search pages displayed by search engines like Google. The agency faulted the companies for failing to identify product names (brand) and not listing potential side effects (only benefits) for the drugs. In other words, the ads lacked “fair balance” something that FDA stresses and that all drug makers are very familiar with. 
The old baseball adage which says that “you can’t tell the players apart without a program” is particularly apt when it comes to tracing the M &A activity that led to the creation of some today's largest pharmaceutical companies.
As you all know by now, 
How many of you read the printed ingredients and nutrition fact boxes found on packaged foods to help you decide which of two similar products you ought to buy? What if the same concept was applied to direct-to-consumer (DTC) prescription drug ads? Do you think that it would be easier to determine which of two similar medications may be best for you? Well, researchers at Dartmouth Medical School think so! And, they are urging the US Food and Drug administration to adopt a similar concept for all DTC advertising.
After having looked at .jpg)
Twitter, the microblogging platform, is the current rage in social media. According to .gif)
In the wake of last week’s Pfizer-Wyeth M&A feeding frenzy, I suspect that most analysts were hoping that this week would be a little quieter. Unfortunately for many pharmaceutical company employees, this week may be shaping up to be almost as nerve-wracking as last week!
While the domino theory was incorrect when it came to the spread of communism during the Cold War, there may be a kernel of truth to it when it is applied to today’s pharmaceutical industry. On Tuesday, Pfizer announced that it would lay off 800 researchers. Not to be outdone by Pfizer,.jpg)
For those of you who haven’t been able to keep up with the latest pharma layoffs, I came across an 
For the past five years, I have been giving career development seminars that offer graduate students and postdoctoral fellows alternate careers choices (instead of research) for life scientists. The intent of these seminars is to get students who may not be enamored with a possible life long career at the bench (I know that there a lot of you out there) to think about what they really want to do after they complete their graduate or postdoctoral training..jpg)
Over the past few weeks, the blogosphere was rife with rumors and speculation that Pfizer would be laying off additional R&D personnel in December. However, it seems that the layoffs have been 
According to a recent analysis conducted by .jpg)
I am frequently asked by life sciences PhDs whether an MBA would improve their chances of finding a job in industry. And, my response is always “maybe— because it depends. I don’t think that getting a traditional MBA really gives you that much of an edge especially if you are an established PhD looking for career advancement or change. However, if you are a graduate student or postdoc who has already decided that academia is not for you, then getting a certificate or M.S. through an established graduate program in biotechnology (
Let me begin with the good news. The Indianapolis Business journal reported today 
First, King Pharmaceuticals posted a non-branded high blood pressure video on YouTube in early 2007. Next, Novartis added a 60-second commercial (as part of its 
ing ideas and tips that I presented in .jpg)
.gif)
